News

Explore insights from six leading epileptologists on the evolution of epilepsy diagnosis and treatment, highlighting innovations and future challenges from the 2024 ILAE Congress.

Epilepsy is one of the most common neurological disorders. Despite its prevalence, widespread misconceptions and social stigma continue to marginalize those living with the condition.

Gender-based violence has a profound impact on women’s mental health, often leading to anxiety, depression, and post-traumatic stress disorder (PTSD).

The United Nations launched this initiative in 2015 to promote gender equality in STEM, an opportunity to support and include women and girls in order for them to receive full and equal access to careers in science.

There are over 50 million people living with epilepsy and over 50% of them will experience some kind of stigma surrounding the illness.

Angelini Pharma has been awarded the prestigious Top Employer certification for the sixth consecutive year.

LIFE-GREENAPI: Innovating for the Future is the title of the event hosted by Angelini Pharma at its Fine Chemicals plant in Aprilia.

Rafal Kaminski contributes an op-ed to Labiotech in which he presents an overview of the current treatment landscape for people living with epilepsy.

Initiated by the European Commission and funded by the Marie Sklodowska Curie Actions (MSCA), European Researchers' Night is the largest science outreach and research event in Europe.

Jacopo Andreose advocates for increased European investment in Mental Health, highlighting its societal and economic benefits in an Op-Ed for Euroactiv.

Launched by the WHO in 2019, World Patient Safety Day is observed annually on 17th September in recognition of patient safety as a large and growing public healthcare challenge.

Organised by the International League Against Epilepsy (ILAE) and held biennially between 7th and 11th September, Angelini Pharma is proud to announce its participation in the 15th EEC.

Brain health and sex and gender differences represent a crucial and innovative area of study in modern medicine.

World Brain Day is a global initiative that occurs annually on 22nd July and is dedicated to raising awareness of the importance of Brain Health and advancing education on neurological diseases.

Identifying new options to increase adherence is vital to the epilepsy community.

Angelini Pharma is proud to announce its participation in the European Academy of Neurology Congress 2024 (EAN), representing Europe’s largest forum for Neurology.

"Heat therapy, a practice that has stood the test of time, offers practical benefits for a variety of musculoskeletal conditions, making it a valuable tool in our field", Prof. Jürgen Freiwald.

Today, May 20th, marks a significant occasion for the medical research community: it’s Clinical Trials Day. Sponsored by the Association of Clinical Research Professionals (ACRP), this event pays tribute to the dedicated scientists and researchers who drive medical progress through clinical trials.

Neurological disorders affect 43.1% of the global population. In this regard, epilepsy continues to be among top 10 most impactful neurological disorders.

This significant achievement underscores the company's ongoing dedication to minimizing the environmental impact of its laboratory space. 

Brain Awareness Week was originally created by the Dana Alliance for Brain Initiatives in 1995 to raise public awareness about the advancements and benefits of brain research.  

Angelini Pharma's participation in the #50MILLIONSTEPS challenge is part of a broader commitment by the company in the fight against epilepsy, a condition affecting fifty million people worldwide.

Angelini Pharma celebrates the event through the words of its researchers.

The challenge will be focused on advanced digital approaches for drug discovery.

The Headway initiative was presented at the Italian Embassy in Paris, bringing to light significant data on epilepsy in France, with a focus on the inclusion of people in the workplace.

Angelini Pharma confirms itself as Top Employer Europe, attesting its leadership in HR strategies in which we prioritize the well-being, growth, and satisfaction of its Angeliners.

In the weeks leading up to International Epilepsy Day on February 12th, Angelini Pharma is reaffirming its commitment to combating the stigma associated with epilepsy.

The Angelini Pharma’s first international standalone event on epilepsy entirely dedicated to HCPs.

Every year, on October 10th, World Mental Health Day provides a great opportunity to increase awareness on mental health issues and underline the necessity of addressing these challenges on a global scale.

Launched back in 2005, the European Researchers' Night has become an annual event that is celebrated across Europe on September 29.

Angelini Pharma has been awarded the prestigious Best in Media Communication 2022 (BIC) certification for the second year in a row. This recognition comes after a rigorous audit process conducted by Eikon Strategic Consulting.

Today, the report of the project “Developing trust and effective care for people with schizophrenia” by Gamian Europe, in collaboration with the European Psychiatric Association and with the support of Angelini Pharma, has been released.

In the light of what has been done so far and considering the evolution of the socio-economic and environmental context, Angelini Pharma starts a European dissemination roadmap of Headway’s key takeway.

Purple Day has been held annually around the world on March 26: tens of thousands of people celebrate this day by wearing something purple and taking part in initiatives on epilepsy.

To mark International Women’s Day, Angelini Pharma is once again at the side of the IBE, to support “Women and Epilepsy”, an awareness project to eliminate the stigma against women with epilepsy.

The terrible earthquake that has claimed tens of thousands of lives in Turkey and Syria is a tragedy that cannot leave us indifferent. We at Angelini Pharma feel the need and responsibility to act concretely.

Today, on the occasion of the International Epilepsy Day, Angelini Pharma amplifies IBE’s raising awareness commitment by sharing videos of steps taken and donated to the campaign.

His arrival ushers us into a new chapter in our history, into a new synthesis of tradition and specialised innovation, at a crucial time for health.

The World Cancer Day (WCD) supports cancer awareness, education, and action to promote treatment, prevention, and care for all patients.

Telemedicine will reduce healthcare waiting lists and “electronic” medicines are already as effective as real ones.

Thanks to the involvement of everyone in the company, together with colleagues from the Angelini Industries Group, the goal will be to total one million steps altogether, counting them via a virtual pedometer.

Angelini Pharma, for the fourth consecutive year, is Top Employer Europe with local certifications in Italy, Spain, Portugal, Poland, Turkey, Germany and Romania.

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval to the extension of the existing indication of Xydalba (dalbavancin) to include the pediatric population.

This project will contribute to sustainable development of pharmaceutical manufacture, use and disposal.

In Spain alone, it is estimated that 400,000 people suffer from epilepsy, a chronic disease that affects more than 50 million people worldwide.

On World Mental Health Day 2022, with the goal of raising awareness around mental health disorders, Angelini Pharma announces its partnership with the on-demand streaming platform CHILI.

A new recognition for Angelini Pharma, confirming once again its commitment to becoming a workplace that is increasingly focused on people's wellbeing.

Angelini Pharma celebrates the event through the words of its researchers.

The presentation event for the new Mental Health Index will be held in Brussels on Sept. 28 and will be available via live streaming on the Harmonia mentis website.

Headway | Focus Epilepsy was conceived to create a multidisciplinary platform for strategic consideration, analysis, dialogue, and comparison between various European experiences in epilepsy management.

Sustainability has become one of the most relevant concepts as it is also intertwined with health. The pandemic unequivocally showed us that there is in fact a correlation between environment and our wellbeing.

The last few turbulent years have accelerated organizations’ digital transformation and Angelini Pharma has embraced this change to become a Digital First company.

The company stood out thanks to its excellent reputational positioning, the positive judgment of journalists, and its ability to effectively communicate.

Headway is a Mental Health initiative launched by The European House Ambrosetti and Angelini Pharma.

After the global communication campaign #ByMyEpilepside, Angelini Pharma adds a new chapter to the story about epilepsy.

The center opens today in Passoscuro, in Fiumicino’s municipality. It’s the first in Lazio Region and the largest in Italy for available places. Angelini Foundation among donors.

Angelini Pharma is providing its support to people affected by the ongoing humanitarian emergency.

On the occasion of International Epilepsy Day 2022, Angelini Pharma reaffirms its commitment to stay close to people with epilepsy launching its disease awareness and communications campaign: #ByMyEpilepside.

February 4th is the day dedicated worldwide to cancer awareness. Every year, the World Cancer Day promotes education, and actions against cancer to make prevention, treatment and care equitable for all.

Issued by the Top Employers Institute, this certification is awarded to all the companies that excel in their HR Practices and that create incentives for the development and well-being of their employees, guaranteeing the best working conditions.  

Angelini Pharma is pleased to announce the appointment of Rafal Kaminski as Chief Scientific Officer. He will join the Company on January 17th.

The National Institute for Health and Clinical Excellence (NICE) has published its final Technology Appraisal Guidance (TAG) for cenobamate.

After more than one hundred years of history, Angelini Group becomes Angelini Industries. At Angelini Pharma we feel proud of being part of the project of this revolution and glad to share the new logo, inspired by our core behavior. 

A week dedicated to raising awareness, analyzing the effects of the pandemic on public mental health, and building a space for debate. These are the main objectives of the initiatives organized by Angelini Pharma on the occasion of World Mental Health Day, our Mental Health Week.

The results of the study have been published online by the journal Epilepsia.

The launch of the new Career Site is part of an employer branding strategy that aims to attract the best candidates through the use of various communication tools and channels, as well as directly meeting young candidates through events organized in partnership with universities, business schools, and private entities.

In this issue, you'll find exciting news and original stories, a focus on our commitment on Epilepsy and our strategy to becoming a recognized Employer of Choice.

In 2020, billions of people faced a global pandemic for the first time in their lives, without having any experience or preparation for it. In this year everyone had to find new emotional, mental and physical resources. Angelini Pharma also wanted to do its part.

We are celebrating International Women's Day today, the annual opportunity to reflect on the progress achieved and call for greater gender equality changes.

Angelini Pharma never stops looking at future, with a foremost attention to innovative solutions and opportunities for identifying and enhancing promising health solutions.

On February 8th, the world celebrates International Epilepsy Day to raise awareness of one of the world's most prevalent neurological diseases.

Cenobamate has received a positive CHMP opinion for the adjunctive treatment of focal onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic products.

For the second consecutive year, Angelini Pharma has obtained the Top Employers Europe 2021 certification.

Angelini Pharma announced today the acquisition of Arvelle Therapeutics, the Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system disorders.

Ovid Therapeutics yesterday announced the topline results from the Company’s Phase III NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome.

November 25th marks the International Day for the Elimination of Violence Against Women, a global and severe issue that affects us all, women and men

The European Commission has approved a deal for GSK to sale its rights for ThermaCare® Heat Wraps to Angelini Pharma.

We are inside the 17,000 m2 of the Amuchina plant in Casella where 38 people produces the wide-spectrum disinfectant Amuchina.

Angelini Pharma has increased production of Amuchina at its Ancona plant and has focused the Casella factory on the production of disinfectants, outsourcing production of detergents.

Angelini Pharma has obtained the Top Employers Europe 2020 certification. The certification is awarded to companies that stand out for the implementation of significant, innovative and effective personnel management practices.

Angelini Farmacéutica takes 24 th place in the ranking of the most respected and recognised pharmaceutical companies in Spain.

The Summit brought together young and motivated psychiatrists from across Europe who are interested in digital developments and innovations in mental health.

Brussels, October 9th, 2019: Angelini Pharma’s international Public Affairs initiative “Headway2020 : A new roadmap in Mental Health” goes public ahead of the 27th World Mental Health Day at the European Parliament.

With healthcare policies, medical guidelines and not surprisingly prescriptions increasingly under scrutiny from both Health Authorities and budget holders, the goals for healthcare professional communications are rapidly changing.

The acquired products include BoxaGrippal® and Heumann.

Angelini supports the Italian Red Cross providing by medicines to people in Venezuela whose lives have been shattered by violence and instability.

On May 17 Angelini Pharma signed a deal with EUSA Pharma to be the exclusive distributor for Fotivda (Tivozanib), a product indicated for first line treatment of adult patients with advanced renal cell carcinoma (RCC)

The Board of Directors of Angelini Holding S.p.A., is pleased to announce that Pierluigi Antonelli has been appointed as the new CEO of Angelini Pharma, effective March 4th, 2019.